JMM - Past and present: Invited comment on W. Ebstein: On the therapy of diabetes mellitus, in particular on the application of sodium salicylate

Journal of Molecular Medicine

Volumn 80, Issue 10, 2002, Pages 618-619

  Shoelson, Steven ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SALICYLATE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT;

AUTOIMMUNE DISEASE; BIOAVAILABILITY; BIOMEDICINE; CLINICAL FEATURE; DISEASE COURSE; EDITORIAL; HUMAN; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MEDICAL LITERATURE; MEDICAL RESEARCH; PANCREAS ISLET BETA CELL; PATHOGENESIS; ARTICLE; DIABETES MELLITUS; HISTORY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIABETES MELLITUS; HISTORY, 19TH CENTURY; HUMANS; SODIUM SALICYLATE;

EID: 0036460073     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-002-0383-x     Document Type: Editorial

References (4)

1. Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956-959
2. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396:77-80
3. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293:1673-1677
4. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321-1326